Acorafloxacin

Drug Profile

Acorafloxacin

Alternative Names: Avarofloxacin; JNJ-32729463; JNJ-32729463-AAA; JNJ-Q2

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen
  • Developer Furiex Pharmaceuticals; Janssen
  • Class Antibacterials; Carboxylic acids; Fluorocarbons; Fluoroquinolones; Piperidines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Community-acquired pneumonia; Skin and soft tissue infections

Most Recent Events

  • 07 May 2014 Avarofloxacin is available for licensing as of 07 May 2014. http://www.furiex.com
  • 25 Feb 2013 Avarofloxacin receives Fast Track designation for Skin and soft tissue infections and Community-acquired pneumonia in USA
  • 25 Feb 2013 Avarofloxacin receives Qualified Infectious Disease Product (QIDP) designation from the US FDA for Skin and soft tissue infections and Community-acquired pneumonia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top